Diagnostic and therapeutic stratification of childhood brain tumors: Implications for translational research

Journal of Child Neurology

Volumn 23, Issue 10, 2008, Pages 1179-1185

  Pollack, Ian F ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Brain tumor; Molecular marker; Pediatric; Prognostic factor

Indexed keywords

CARBOPLATIN; CYCLOOXYGENASE 2 INHIBITOR; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; GADOLINIUM TEXAPHYRIN; GEFITINIB; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; ISOTRETINOIN; LAPATINIB; LENALIDOMIDE; LOMUSTINE; LONAFARNIB; METHOTREXATE; MOLECULAR MARKER; PLATINUM COMPLEX; PROCARBAZINE; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TIOGUANINE; TIPIFARNIB; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

BRAIN STEM TUMOR; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; GLIOBLASTOMA; GLIOMA; HIGH RISK PATIENT; HUMAN; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD; DRUG DESIGN; DRUG THERAPY; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PROGNOSIS; RADIOTHERAPY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 53549107181     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073808321770     Document Type: Conference Paper

References (57)

1. Pollack IF Brain tumors in children. N Engl J Med. 1994; 331: 1500-1507.
2. Jennings MT, Sposto R., Boyett JM, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: Phase II study CCG-9941 of the Children's Cancer Group. J Clin Oncol. 2002; 20: 3431-3437.
3. Radcliffe J., Packer RJ, Atkins TE, et al. Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol. 1992; 32: 551-554.
4. Evans AE, Jenkin RD, Sposto R., et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg. 1990; 72: 572-582.
5. Tait DM, Thornton-Jones H., Bloom HJG, Lemerle J., Morris-Jones P. Adjuvant chemotherapy for medulloblastoma: The first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer. 1990; 26: 464-469.
6. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol. 1999; 17: 832-845.
7. Packer R., Gajjar A., Vezina G., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy regimens for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006; 24: 4202-4208.
8. Pizer BL, Weston CL, Robinson KJ, et al. Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/ UKCCSG PNET 3 study. Eur J Cancer. 2006; 42: 1120-1128.
9. Thomas RM, Deutsch M., Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol. 2000; 18: 3004-3011.
10. Gajjar A., Hernan R., Kocak M., et al. Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004; 22: 984-993.
11. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 1997; 57: 3272-3280.
12. Grotzter MA, Janss AJ, Fung K., et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol. 2000; 18: 1027-1035.
13. MacDonald TJ, Brown KM, LaFleur B., et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet. 2001; 29: 143-152.
14. Pomeroy S., Goumnerova LC, Tamayo P., et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002; 415: 436-442.
15. Northcott P., Nakahara Y., Peacock J., et al. Identification of known and novel recurrent amplified oncogenes in pediatric medulloblastoma [abstract]. Neuro Oncol. 2007; 9: 554.
16. Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SL Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A. 1994; 91: 12867-12871.
17. Miralbell R., Fitzgerald TJ, Laurie F., et al. Radiotherapy in pediatric medulloblastoma: Quality assessment of Pediatric Oncology Group Trial 9031. Int J Radiat Oncol Biol Phys. 2006; 64: 1325-1330.
18. Taylor RE, Bailey CC, Robinson KJ, et al. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer. 2005; 41: 727-734.
19. Jakacki R., Burger P., Zhou T., et al. Outcome for metastatic (M+) medulloblastoma (MB) treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide (CPM) and vincristine (VCR). J Clin Oncol. 2007; 25: 75S.
20. Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science. 2002; 297: 1559-1561.
21. Hallahan AR, Pritchard JI, Hansen S., et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 2004; 64: 7794-7800.
22. Finlay JL, Boyett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol. 1995; 13: 112-123.
23. MacDonald TJ, Arenson EB, Ater J., et al. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: Final analysis of Children's Cancer Group Study 9933. Cancer. 2005; 104: 2862-2871.
24. Sposto R., Ertel IJ, Jenkin RD, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol. 1989; 7: 165-177.
25. Wisoff JH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: A report of the Children's Cancer Group trial no. CCG-945. J Neurosurg. 1998; 89: 52-59.
26. Pollack IF, Finkelstein SD, Woods J., et al. Expression of p53 and prognosis in malignant gliomas in children. N Engl J Med. 2002; 346: 420-427.
27. Pollack IF, Hamilton RL, Burnham J., et al. The impact of proliferation index on outcome in childhood malignant gliomas: Results in a multi-institutional cohort. Neurosurgery. 2002; 50: 1238-1244.
28. Pollack IF, Hamilton RL, Sobol RW, et al. MGMT expression strongly correlates with outcome in childhood malignant gliomas: Results from the CCG-945 cohort. J Clin Oncol. 2006; 24: 3431-3437.
29. Stupp R., Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med. 2005; 352: 987-996.
30. Jakacki R., Yates A., Zhou T., et al. Temozolomide as part of combination chemotherapy for pediatric brain tumors: The Children's Oncology Group experience [abstract]. Neuro Oncol. 2007; 9: 188.
31. Faury D., Nantel A., Dunn SE, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007; 25: 1196-1208.
32. Khatua S., Peterson KM, Brown KM, et al. Overexpression of the EGFR/ FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res. 2003; 63: 1865-1870.
33. Wong KK, Tsang YTM, Chang YM, et al. Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res. 2006; 66: 11172-11178.
34. Fouladi M., Nicholson HS, Zhou T., et al. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: A Children's Oncology Group study. Cancer. 2007; 110: 2535-2541.
35. Kieran MW, Packer RJ, Onar A., et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: A Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007; 25: 3137-3143.
36. Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007; 9: 145-160.
37. Epstein F., McCleary EL Intrinsic brain-stem tumors of childhood: surgical indications. J Neurosurg. 1986; 64: 11-15.
38. Pollack IF, Hoffman HJ, Humphreys RP, Becker L. The long-term outcome after surgical treatment of dorsally exophytic brain-stem gliomas. J Neurosurg. 1993; 78: 859-863.
39. Dunkel IJ, Garvin JH, Goldman S., et al. High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. J Neurooncol. 1998; 37: 67-73.
40. Jenkin RD, Boesel C., Ertel I., et al. Brain-stem tumors in childhood: A prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group. J Neurosurg. 1987; 66: 227-233.
41. Kretschmar CS, Tarbell NJ, Barnes PD, Krischer JP, Burger PC, Kun L. Pre-irradiation chemotherapy and hyperfractionated radiation therapy 66Gy for children with brain stem tumors. Cancer. 1993; 72: 1404-1413.
42. Needle MN, Mehta M., Krailo M., et al. Phase I study of topotecan as a radiosensitizer prior to daily involved field irradiation in children with intrinsic pontine glioma. A Children's Cancer Group study [abstract]. Proc Am Soc Clin Oncol. 1999; 18: 558a.
43. Sanghavi SN, Needle MN, Krailo MD, et al. A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: First report of CCG-0952. Neuro Oncol. 2003; 1: 8-13.
44. Mehta M., Forouzannia A., Ames M., et al. Phase I study of motexafin-gadolinium (M-Gd) as a radiosensitizer for pediatric intrinsic pontine glioma (BSG): A Children's Oncology Group Study. Proc Am Soc Clin Oncol. 2001; 20: 243a.
45. Gilbertson RJ, Hill A., Hernan R., et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res. 2003; 9: 3620-3624.
46. Packer RJ, Ater J., Allen J., et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997; 56: 747-754.
47. Prados MD, Edwards MS, Rabbitt J., Lamborn K., Davis RL, Levin VA Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol. 1997; 32: 235-241.
48. Ater J., Holmes E., Zhou T., et al. Treatment of young children with progressive or symptomatic low-grade glioma with chemotherapy: preliminary report from the Children's Oncology Group (COG) Phase 3 protocol A9952. Neuro Oncol. 2006; 8: 465.
49. Bouffet E., Goldman S., Jakacki R., et al. Pilot study of vinblastine in patients with recurrent and refractory low grade glioma. Neuro Oncol. 2004; 6: 450.
50. Wong KK, Chang YM, Tsang YTM, et al. Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide micro-array reveals two potential subgroups. Cancer Res. 2005; 65: 76-84.
51. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. New Engl J Med. 1993; 328: 1725-1731.
52. Geyer JR, Sposto R., Jennings M., et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: A report from the Children's Cancer Group. J Clin Oncol. 2005; 23: 7621-7631.
53. Rutkowski S., Bode U., Deinlein F., et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. New Engl J Med. 2005; 352: 978-986.
54. Biegel JA, Zhou J. -Y, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999; 59: 74-79.
55. Judkins AR, Burger PC, Hamilton RL, et al. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol. 2005; 64: 391-397.
56. Hilden JM, Meerbaum S., Burger P., et al. Central nervous system atypical teratoid/rhabdoid tumor: Results of therapy in children enrolled in a registry. J Clin Oncol. 2004; 22: 2877-2884.
57. Tekautz TM, Fuller CE, Blaney S., et al. Atypical teratoid/rhabdoid tumors (ATRT): Improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005; 23: 1491-1499.